Top Markets
#1 GEKKO GEKKO +53.94%
#2 Helium Helium +50.00%
#3 TENDIES TENDIES +45.07%
#4 Pons Pons +39.32%
#5 ADO Protocol ADO Protocol +39.07%
#6 Prom Prom +31.43%
#7 Collector Crypt Collector Crypt +21.07%
#8 o1.exchange o1.exchange +20.78%
#9 Nillion Nillion +20.10%
#10 龙虾 (Lobster) 龙虾 (Lobster) +18.75%
Coin of the day
GEKKO GEKKO
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Jiangsu Yahong Meditech Co Ltd Jiangsu Yahong Meditech Co Ltd

Jiangsu Yahong Meditech Co Ltd

688176
Rang in Aktien #9583
Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong... Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III trials for the treatment of non-muscle invasive bladder cancer. Another promising candidate, APL-1501, an oral MetAP inhibitor, is currently in Phase I testing for addressing urinary system tumors and drug-resistant urinary tract infections. Furthermore, APL-1702, a photodynamic therapy product, is in Phase III for tackling cervical high-grade squamous intraepithelial lesions that arise from HPV infections. Beyond these clinical programs, Jiangsu Yahong Meditech is actively exploring targeted protein degraders in its preclinical phase. This includes ASN-1764, aimed at triple-negative breast cancer; ASN-1780, intended for metastatic castration-resistant prostate cancer; and APL-1901, designed to treat ER-positive breast cancer. The company's developmental efforts also encompass APL-1401, targeting moderately to severely active ulcerative colitis, and ASN-1733, for combating Acinetobacter baumannii infection.
Aktienkurs
$1.72
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$985.07M
Veränderung (1 Tag)
-0.50%
Veränderung (1 Jahr)
6.01%
Land
CN
Handel Jiangsu Yahong Meditech Co Ltd (688176)

Kategorie

Healthcare
Kursverlauf für Jiangsu Yahong Meditech Co Ltd (688176)
Höchster Schlusskurs: $1.81 am 2026-08-01

Niedrigster Schlusskurs: $2.70 am 2022-01-01
Kursverlauf der Aktie von Jiangsu Yahong Meditech Co Ltd von 2022 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 14.02%
2025 47.19%
2024 -34.35%
2023 -4.03%
2022 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 $171.67 -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 $166.36 31.46%
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 $37.84 25.87%
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 $222.33 27.49%
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $21.19 17.16%
IN